Epigenetics

Epigenetics is the control of gene expression without altering the DNA sequence, including DNA methylation, genomic imprinting, maternal effects, gene silencing, nucleolus dominant, dormant transposon activation, and RNA editing. In contrast to classical genetics, which focuses on the effects of gene sequences on biological functions, epigenetics focuses on the mechanisms by which these "epigenetic phenomena" are established and maintained.

Cat. No.	Product name
BP14095	PF-06726304
BP14095	PF-06726304 shows robust antitumor growth activity. PF-06726304 is an effective and selective EZH2 inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 (Kis: 0.7 and 3.0 nM, respectively).
BP14094	PF-06726304 acetate
BP14094	PF-06726304 acetate is a selective inhibitor of EZH2, with robust antitumor growth activity.
BP14093	PF-06409577
BP14093	PF-06409577 is an effective, orally active, and specific allosteric activator of AMPK (EC50: 7 nM, for α1β1γ1).
BP14092	Pep2m, myristoylated acetate
BP14092	Pep2m, myristoylated acetate is a Cell-permeable, myristoylated form of pep2m. Peptide inhibitor of the interaction between the C-terminus of the GluA2 (AMPA receptor) subunit and N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates AMPA receptor function. Reduces postsynaptic currents in CA1 neurons, AMPA-mediated currents in cultured hippocampal neurons and AMPA receptor surface expression.
BP14091	PCI-34051
BP14091	PCI-34051 is an effective and selective HDAC8 inhibitor (IC50: 10 nM).
BP14090	Abexinostat
BP14090	PCI-24781 (Abexinostat) is a new pan-HDAC inhibitor mainly targeting HDAC1 (Ki: 7 nM), also have moderate inhibitory for HDACs 2, 3, 6, and 10 and greater than 40-fold selectivity against HDAC8. Phase 1/2.
BP14089	PBIT
BP14089	PBIT inhibits JARID1B histone demethylase (IC50 of about 3 μM). PBIT also inhibits JARID1A and JARID1C (IC50s of 6 μM and 4.9 μM, respectively). PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (JARID1) enzymes.
BP14088	PARP1-IN-8
BP14088	PARP1-IN-8 is an effective inhibito of PARP1 (IC50 = 97 nM).
BP14087	PARP1-IN-5 dihydrochloride
BP14087	PARP1-IN-5 dihydrochloride is an orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer.
BP14086	PARP14 inhibitor H10
BP14086	PARP14 inhibitor H10 is a selective inhibitor against PARP14 with IC50 of 490 nM
BP14085	Palmitelaidic Acid
BP14085	Palmitelaidic Acid is one of the most abundant fatty acids in serum and tissue.
BP14084	CBP/p300-IN-5
BP14084	P300/CBP-IN-5 is a potent inhibitor of p300/CBP histone acetyltransferase (IC50 of 18.8 nM).
BP14083	CBP/p300-IN-3
BP14083	P300/CBP-IN-3 is an inhibitor of p300/CBP histone acetyltransferase.
BP14082	OXFBD04
BP14082	OXFBD04 is a potent and selective inhibitor of BRD4(IC50 of 166 nM).
BP14081	Oxamflatin
BP14081	Oxamflatin is an effective inhibitor of HDAC (IC50: 15.7 nM).
BP14080	OUL35
BP14080	OUL35 is a selective PARP-10 inhibitor, and small-molecule ARTD10 inhibitor. OUL35 has been shown to rescue cells from ARTD10-induced cell death.
BP14079	OSS_128167
BP14079	OSS_128167 is a specific SIRT6 inhibitor, and for SIRT6(IC50=89 μM), SIRT1(IC50=1578 μM) and SIRT2(IC50=751 μM).
BP14078	Iadademstat dihydrochloride
BP14078	ORY-1001, a Potent and Selective Covalent KDM1A/LSD1 Inhibitor, for the Treatment of Acute Leukemia.
BP14077	ORY1001
BP14077	ORY-1001 (RG-6016) is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor, with high selectivity against related FAD dependent aminoxidases with IC50 of <20 nM.
BP14076	Ophiopogonin D'
BP14076	Ophiopogonin D' can activate SIRT1 in a dose-dependent manner. Ophiopogonin D' also noncompetitively inhibits UGT1A6 and UGT1A10.